Allogene Therapeutics, Inc.

NasdaqGS:ALLO Stock Report

Market Cap: US$336.8m

Allogene Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ALLO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
21 Apr 25SellUS$13,537Annie YoshiyamaIndividual9,601US$1.41
14 Mar 25SellUS$10,839Benjamin BeneskiIndividual5,488US$1.98
14 Mar 25SellUS$91,469David ChangIndividual46,668US$1.96
03 Feb 25SellUS$32,014Zachary RobertsIndividual18,832US$1.70
03 Feb 25SellUS$25,216Timothy MooreIndividual14,746US$1.71
03 Feb 25SellUS$7,545Geoffrey ParkerIndividual4,361US$1.73
03 Feb 25SellUS$10,951Earl DouglasIndividual6,404US$1.71
03 Feb 25SellUS$77,285David ChangIndividual46,003US$1.68
21 Jan 25SellUS$48,414Zachary RobertsIndividual27,199US$1.78
09 Dec 24SellUS$19,916Deborah MessemerIndividual9,136US$2.18
05 Dec 24SellUS$19,917Franz HumerIndividual9,221US$2.16
30 May 24SellUS$26,181Franz HumerIndividual11,200US$2.34
16 May 24BuyUS$4,999,997Vida Ventures Advisors, LLCCompany1,724,137US$2.90

Insider Trading Volume

Insider Buying: ALLO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ALLO?
Owner TypeNumber of SharesOwnership Percentage
Public Companies1,156,6890.532%
Individual Insiders19,009,4208.75%
General Public28,631,00213.2%
VC/PE Firms40,748,34618.8%
Institutions127,719,28158.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.3%.

Top Shareholders

Top 25 shareholders own 73.34% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.1%
Pfizer Venture Investments LLC
22,032,040US$34.1m0%5.08%
8.61%
TPG Capital, L.P.
18,716,306US$29.0m0%0.1%
5.27%
BlackRock, Inc.
11,450,079US$17.7m-36.6%no data
5.01%
Lynx1 Capital Management LP
10,874,723US$16.9m75.3%6.83%
4.71%
FMR LLC
10,225,851US$15.9m-57%no data
3.77%
David Chang
8,189,765US$12.7m47%no data
3.68%
The Vanguard Group, Inc.
8,000,692US$12.4m-3.93%no data
3.34%
State Street Global Advisors, Inc.
7,249,966US$11.2m3.38%no data
3.17%
Capital Research and Management Company
6,896,552US$10.7m0%no data
2.99%
Arie Belldegrun
6,499,898US$10.1m14.4%no data
2.46%
Citadel Advisors LLC
5,349,096US$8.3m6.14%0.01%
2.27%
PRIMECAP Management Company
4,927,340US$7.6m-13.1%0.01%
2.06%
T. Rowe Price Group, Inc.
4,485,572US$7.0m-7.3%no data
2.01%
Woodline Partners LP
4,360,232US$6.8m-0.09%0.05%
1.64%
JP Morgan Asset Management
3,572,112US$5.5m-8.85%no data
1.64%
Dimensional Fund Advisors LP
3,561,626US$5.5m30.4%no data
1.59%
Foresite Capital Management, LLC
3,448,275US$5.3m0%1.49%
1.49%
Geode Capital Management, LLC
3,232,618US$5.0m0.17%no data
1.34%
Wildcat Capital Management, LLC
2,920,787US$4.5m0%2.62%
1.32%
Frazier Life Sciences Management, LP
2,867,750US$4.4m0%0.2%
1.25%
Two Sigma Investments, LP
2,712,139US$4.2m-3.07%0.01%
1.24%
Two Sigma Advisers, LP
2,702,200US$4.2m12.1%0.01%
0.83%
Vida Ventures Advisors, LLC
1,798,163US$2.8m-49%11.83%
0.81%
Goldman Sachs Group, Investment Banking and Securities Investments
1,769,069US$2.7m0%no data
0.69%
Vestal Point Capital, LP
1,500,000US$2.3m0%0.15%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/27 05:04
End of Day Share Price 2025/04/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allogene Therapeutics, Inc. is covered by 31 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Shanshan XuBerenberg
Jason Matthew GerberryBofA Global Research